NeuroSense Wins Australian Patent for PrimeC; Shares Tick Higher

Australian patent grant extends PrimeC intellectual property protection through October 2042 and follows an earlier U.S. patent

By Avery Klein NRSN

NeuroSense Wins Australian Patent for PrimeC; Shares Tick Higher

NRSN

NeuroSense Therapeutics saw its stock rise after the Australian Patent Office issued a patent covering its PrimeC extended-release oral therapy. The patent provides protection through October 2042 and complements an earlier U.S. patent as the company advances PrimeC toward Phase 3 testing in amyotrophic lateral sclerosis and pursues applications in other neurodegenerative diseases.

Key Points

Australian Patent No. 2022370513 granted for PrimeC - "Compositions Comprising Ciprofloxacin and Celecoxib" - protection through October 2042.
The Australian patent follows an already granted U.S. patent and is part of NeuroSense's strategy to expand PrimeC intellectual property across key markets.
PrimeC is an oral extended-release combination of ciprofloxacin and celecoxib, positioned as Phase 3-ready for ALS after positive Phase 2b PARADIGM results and FDA clearance of the Phase 3 protocol; development also targets Alzheimer’s and other neurodegenerative diseases.

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) shares rose 3.9% on Monday after the company announced that the Australian Patent Office had granted intellectual property protection for its PrimeC therapy.

The patent issued is Australian Patent No. 2022370513, titled "Compositions Comprising Ciprofloxacin and Celecoxib," and it confers coverage through October 2042. The company said the Australian grant follows a previously issued U.S. patent and represents a deliberate step to broaden PrimeC's IP footprint in important jurisdictions.

In a company statement, Chief Executive Officer Alon Ben-Noon said: "Securing patent protection in Australia, in addition to the already granted patent in the US, is an important step in executing our global IP protection strategy for PrimeC."

About PrimeC

PrimeC is an oral, extended-release formulation that combines the antibiotics ciprofloxacin and the anti-inflammatory celecoxib. The therapy is designed to act on several biological pathways implicated in amyotrophic lateral sclerosis (ALS), including neuroinflammation, iron dysregulation, and miRNA dysregulation.

The company describes PrimeC as Phase 3-ready for ALS after reporting positive results from its Phase 2b PARADIGM study and obtaining FDA clearance of the pivotal Phase 3 protocol. NeuroSense is also pursuing PrimeC's development for Alzheimer’s disease and other neurodegenerative conditions.

Market reaction and context

The patent announcement coincided with a modest uptick in NeuroSense's NASDAQ-listed shares. The Australian grant augments existing U.S. protection and aligns with the company's stated global IP strategy for the compound.

Limitations of available information

The company has not provided additional details beyond the patent number, title, term through October 2042, the prior U.S. patent, the Phase 2b result characterization, and FDA clearance of the Phase 3 protocol. No further claims about timing, commercial exclusivity beyond the stated term, or clinical outcomes beyond Phase 2b and Phase 3 readiness were provided in the announcement.

Risks

Patent protection referenced in the announcement specifically covers Australia (and the company noted a prior U.S. patent); the scope and duration of exclusivity outside these jurisdictions were not detailed.
While described as Phase 3-ready following Phase 2b PARADIGM results and FDA clearance of the Phase 3 protocol, final clinical efficacy and regulatory approval remain to be determined in Phase 3 trials.
The company provided limited additional detail in the announcement, leaving questions about commercialization timing, market access, and potential competitive responses unaddressed.

Menu

NeuroSense Wins Australian Patent for PrimeC; Shares Tick Higher

Key Points

Risks

More from Stock Markets